Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2479人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866560, encodeId=aa861866560c3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, objectType=article, longId=301255, objectId=1a8d30125528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a8d30125528, replyNumber=0, likeNumber=98, createdTime=2022-08-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a8d30125528, moduleTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a8d30125528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866285, encodeId=5f37186628565, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！, objectType=article, longId=218576, objectId=495e2185e650, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495e2185e650, replyNumber=0, likeNumber=63, createdTime=2022-09-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495e2185e650, moduleTitle=J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=495e2185e650)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866123, encodeId=fa4d186612335, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, objectType=article, longId=213145, objectId=141f2131458b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141f2131458b, replyNumber=0, likeNumber=107, createdTime=2022-02-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141f2131458b, moduleTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141f2131458b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866294, encodeId=7e76186629410, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=76, createdTime=2022-07-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866493, encodeId=2e2d1866493dd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：临床试验表明女性患者接受抗肿瘤治疗更容易出现严重不良反应, objectType=article, longId=295164, objectId=f6bf295164d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6bf295164d4, replyNumber=0, likeNumber=115, createdTime=2022-03-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6bf295164d4, moduleTitle=J Clin Oncol：临床试验表明女性患者接受抗肿瘤治疗更容易出现严重不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6bf295164d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866117, encodeId=2a4f186611eec, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后, objectType=article, longId=212904, objectId=f025212904a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f025212904a5, replyNumber=0, likeNumber=66, createdTime=2022-01-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f025212904a5, moduleTitle=J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f025212904a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866274, encodeId=2a7c18662e4b8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=71, createdTime=2021-11-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866387, encodeId=3579186638e5b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：他汀类药物对前列腺癌筛查的影响, objectType=article, longId=221335, objectId=f890221335a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f890221335a4, replyNumber=0, likeNumber=101, createdTime=2022-05-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f890221335a4, moduleTitle=JAMA Oncol：他汀类药物对前列腺癌筛查的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f890221335a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866209, encodeId=737b1866209ac, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：依鲁替尼治疗可明显增加CLL患者的房颤、出血和心衰风险, objectType=article, longId=216573, objectId=ffbb2165e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffbb2165e301, replyNumber=0, likeNumber=126, createdTime=2022-04-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffbb2165e301, moduleTitle=J Clin Oncol：依鲁替尼治疗可明显增加CLL患者的房颤、出血和心衰风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffbb2165e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866154, encodeId=4b91186615417, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=76, createdTime=2022-04-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866234, encodeId=160518662347f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=53, createdTime=2021-10-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866520, encodeId=09161866520cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, objectType=article, longId=299456, objectId=55f52994568e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f52994568e, replyNumber=0, likeNumber=63, createdTime=2022-04-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f52994568e, moduleTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55f52994568e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866499, encodeId=b95e18664999b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, objectType=article, longId=295362, objectId=66af295362ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66af295362ac, replyNumber=0, likeNumber=73, createdTime=2022-09-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66af295362ac, moduleTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66af295362ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=73, createdTime=2022-09-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866419, encodeId=636b1866419a2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：基于SEER数据库分析子宫内膜癌的临床特征和预后, objectType=article, longId=292099, objectId=d3972920991a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3972920991a, replyNumber=0, likeNumber=74, createdTime=2022-05-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3972920991a, moduleTitle=Front Oncol：基于SEER数据库分析子宫内膜癌的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3972920991a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：分析2019年全球疾病负担，肺癌导致的DALYs为4590万！, objectType=article, longId=293389, objectId=dfb12933898c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfb12933898c, replyNumber=0, likeNumber=71, createdTime=2022-05-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfb12933898c, moduleTitle=JAMA Oncol：分析2019年全球疾病负担，肺癌导致的DALYs为4590万！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfb12933898c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866194, encodeId=5ce618661945f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因, objectType=article, longId=215676, objectId=b05a2156e625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05a2156e625, replyNumber=0, likeNumber=81, createdTime=2022-01-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05a2156e625, moduleTitle=Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b05a2156e625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866240, encodeId=378a1866240f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Gynecol Oncol：半定量法评估血管淋巴管间隙（LVSI）浸润在早期宫颈癌预后预判中的价值, objectType=article, longId=217451, objectId=8e4b21e4510b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e4b21e4510b, replyNumber=0, likeNumber=83, createdTime=2021-11-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e4b21e4510b, moduleTitle=Gynecol Oncol：半定量法评估血管淋巴管间隙（LVSI）浸润在早期宫颈癌预后预判中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e4b21e4510b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866328, encodeId=a55b1866328b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, objectType=article, longId=219570, objectId=1d282195e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d282195e0e7, replyNumber=0, likeNumber=99, createdTime=2022-01-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d282195e0e7, moduleTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d282195e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866279, encodeId=40ef18662e972, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, objectType=article, longId=218300, objectId=ec13218300e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec13218300e1, replyNumber=0, likeNumber=87, createdTime=2022-01-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec13218300e1, moduleTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec13218300e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效

2022-08-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！

2022-09-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L

2022-02-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-07-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：临床试验表明女性患者接受抗肿瘤治疗更容易出现严重不良反应

2022-03-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后

2022-01-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2021-11-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：他汀类药物对前列腺癌筛查的影响

2022-05-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：依鲁替尼治疗可明显增加CLL患者的房颤、出血和心衰风险

2022-04-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2022-04-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2021-10-31

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异

2022-04-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效

2022-09-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-09-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：基于SEER数据库分析子宫内膜癌的临床特征和预后

2022-05-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：分析2019年全球疾病负担，肺癌导致的DALYs为4590万！

2022-05-16

docwu2019 (审核中...)

前往app查看评论内容

#Oncol#

Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因

2022-01-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Gynecol Oncol：半定量法评估血管淋巴管间隙（LVSI）浸润在早期宫颈癌预后预判中的价值

2021-11-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理

2022-01-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响

2022-01-02

科室
- - 订阅+
  - 更多科室
工具
服务